Skip to content

Evaluation of the Role of Brain Natriuretic Peptide in Acute Coronary Syndrome .

Evaluation of the Role of Brain Natriuretic Peptide in Acute Coronary Syndrome .

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06734416
Enrollment
100
Registered
2024-12-16
Start date
2025-01-01
Completion date
2026-03-01
Last updated
2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndromes

Keywords

Brain natriuretic peptide

Brief summary

The measurements of the natriuretic peptide are useful and beneficial for risk stratification irrespective of the cause during admission time or during hospital stay course. the aim of the study is to Assessment of the role of Brain natriuretic peptide in diagnosis of acute coronary syndrome . Evaluation of the relation of Brain natriuretic peptide to the severity and occurrence of complications in acute coronary syndrome .

Detailed description

Ischemic heart disease (IHD) is regarded as one of the important leading causes of disability and death across the globe. Acute coronary syndrome (ACS) applies to a variety of events reporting ischemia, ranging from stable angina without myocardial necrosis to ST -segment elevation myocardial infarction (STEMI). The need for prevention and detection of coronary vascular disease as early as possible by using newer and more cost effective tools is suggested . For risk stratification in patients with ACS, serial ECG monitoring and cardiac biomarkers measurement are needed as part of the diagnostic workup. B-type natriuretic peptide is synthesized as a high molecular weight precursor pro-brain natriuretic peptide (BNP) which is cleaved to release BNP and the amino-terminal fragment, N-terminal pro (NT-pro) BNP. Both peptides are released from the cardiac ventricles in response to the increased wall stress and hence its levels may indicate ventricular strain BNP is believed to have its role as natriuretic hormone and vasodilation. Among other effects are inhibition of the Renin Angiotensin-Aldosterone system(RAAS), and sympathetic nervous system. After an ischemic occurrence, BNP levels peak in 14 to 40 hours .

Interventions

None listed

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* patients with acute coronary syndrome.

Exclusion criteria

* Patients with previous MI * Eection fraction (EF) less than 30% * Patients having cardiomyopathy * Patients having renal, liver, malignant, infectious, or inflammatory diseases .

Design outcomes

Primary

MeasureTime frameDescription
Brain natriuretic peptide level in bloodbaselinelevel of Brain natriuretic peptide in acute coronary syndrome patients.

Contacts

Primary ContactMennat-Allah Gamal kamel Mohamed, resident doctor
mennagamalkamel@gmail.com+201098695613

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026